New Alzheimer's drug studies offer patients hope

New effective medicine could be available in 3-5 years

Dec. 3, 2012
This undated image provided by Merck & Co., shows a cross section of a normal brain (right) and one of a brain damaged by advanced Alzheimer's disease. Alzheimer's patients and their families, desperate for an effective treatment for the epidemic disease, there's hope from new studies starting up and insights from recent ones that didn't quite pan out. (AP Photo/Merck & Co.) / AP

Join the conversation

Alzheimer’s is a frightening disease that leaves families
worried, frazzled and isolated. We’re here to give you the
latest on research, tools for coping and a forum to talk about
the disease and its effect on your lives. Join The Post-Crescent for an ongoing conversation about dementia on Facebook by typing “Living With Dementia” in the subject line.

In the Moment

In October 2011, in a special report called, “In the Moment,” The Post-Crescent introduced readers to a Fox Valley couple facing dementia. To read more about their lives, go to

Alzheimer’s by the numbers

A look at some facts and figures about Alzheimer’s disease, the only illness among the top 10 killers of Americans for which there’s no cure or even a way to slow disease progression:
Human toll: About 5.4 million Americans are suffering with Alzheimer’s disease, including 200,000 under age 65. The total is expected to skyrocket to 16 million by 2050. Alzheimer’s deaths jumped 66 percent from 2000 to 2008. Worldwide, Alzheimer’s accounts for half to three-quarters of the roughly 35 million cases of dementia.
Prevalence: One in eight Americans age 65 or older has Alzheimer’s; nearly half those 85 or older have the neurodegenerative disease. Every 68 seconds, another American develops Alzheimer’s.
On their own: About 800,000 U.S. Alzheimer’s patients, or more than one in seven, live alone, and many don’t have a regular caregiver. That puts them at higher risk than other Alzheimer’s patients for falls, malnutrition, wandering off unattended, untreated medical conditions and accidental death.
Family burden: Last year, about 15 million family and friends provided more than 17 billion hours of unpaid care — valued at about $210 billion — to people with Alzheimer’s and dementia. Many caregivers suffer from depression and high emotional stress, and that physical and emotional toll led to nearly $9 billion in additional health care costs for those caregivers in 2011.
Financial burden: Direct costs to care for U.S. Alzheimer’s patients are estimated at $200 billion this year, including about $140 billion covered by Medicare or Medicaid. Unless treatments to slow, stop or prevent Alzheimer’s are developed, care is expected to cost $1.1 trillion, in today’s dollars, by 2050.
Related costs: Most Alzheimer’s patients have at least one other serious medical problem, and dementia makes treatment for those conditions more complicated. For example, among seniors with diabetes, it costs Medicare 81 percent more to care for one who also has Alzheimer’s.
Source: Alzheimer’s Association,


TRENTON, N.J. — For Alzheimer’s patients and their families desperate for an effective treatment for the epidemic disease, there’s hope from new studies starting up and insights from recent ones that didn’t quite pan out.

If the new studies succeed, a medicine that slows or even stops progression of the brain-destroying disease might be ready in three to five years, said Dr. William H. Thies, chief medical officer of the Alzheimer’s Association. The group assists patients and caregivers, lobbies for more research and helps fund studies.

“The number of smart people working on this problem means to me we’ll begin to manage it better in the very near future,” Thies said. “It may be as short as three years away.”

That’s only if government and other sources provide tens of millions of dollars for additional research and more patients join clinical studies.

After decades of stumbles and dozens of promising experimental drugs failing, scientists think they’re now on the right track. They’re targeting what they think are the mechanisms to arrest a disease that steadily steals patients’ personality and ability to remember, think and care for themselves.

A vaccine is in mid-stage testing, and drugmakers shy about funding expensive treatment tests could start as many as 30 studies once they’re more confident that their approach is sound, Thies said. Early next year, the first study to try to prevent Alzheimer’s begins — in people a decade away from symptoms but who have a genetic mutation that causes early onset Alzheimer’s. It will include three drugs that each attack the country’s No. 6 killer in a different way.

And in May, the Obama administration unveiled an ambitious national plan to fund new research and better train those caring for Alzheimer’s patients.

The number of Alzheimer’s patients in the U.S. is expected to jump from 5.4 million to 16 million by 2050. Costs for care, mostly borne by taxpayers, could skyrocket from roughly $200 billion this year to $1.1 trillion in 2050. The few treatments available only ease symptoms temporarily.

On Monday, drugmaker Merck & Co. announced it’s just begun the first combined mid- and late-stage study of a BACE inhibitor. That’s a new type of drug designed to slow mental and functional decline by limiting production of amyloid beta, the protein that’s the main ingredient in brain-damaging amyloid plaques considered the most likely cause of Alzheimer’s.

After safety testing of the drug MK-8931 in about 200 patients, the 78-week study, known by the acronym EPOCH, will quickly expand to as many as 1,700 patients. That phase will test the daily pill at three different doses, compared with a dummy pill.

Combining study phases should shave some time from the years-long, and often billion-dollar, research process. If MK-8931 works, EPOCH would give Merck one of the two major patient studies needed to win approval from government regulators, said Darryle D. Schoepp, Merck’s head of neuroscience research. Merck also has some backup compounds and plans other studies, including some on patients very early in the disease, Schoepp told The Associated Press in an exclusive interview.

In earlier research, MK-8931 blocked formation of almost all the toxic amyloid plaques, he said.

“No one’s ever done that before,” Schoepp said. “If (amyloid) plaques are the cause, the medicine will work.”

Merck’s MK-8931 and some other experimental drugs aim to turn off the Alzheimer’s “faucet” by blocking production of amyloid beta. Other experimental drugs instead aim to bail out the sink while the faucet’s still running, either by removing clumps of amyloid plaque from the brain or by binding to bits of amyloid beta protein and clearing them from the brain before they clump into plaques.

Researchers were frustrated this year by failures of two drugs that targeted amyloid beta — bapineuzumab from Pfizer Inc. and Johnson & Johnson, and solanezumab from Eli Lilly and Co. Both drugs are injected because their large molecules can’t pass through the digestive tract into blood vessels. Their size might have limited how much medicine could get inside brain cells.

However, solanezumab showed signs that attacking beta amyloid beta was effective. While it didn’t help most patients in the study, it slowed mental decline by about a third in patients with mild forms of the disease — a first for that approach.

That’s added to researchers’ growing belief that patients must be treated early on, before Alzheimer’s has destroyed much of their brains.

The big prevention study to start early next year, called DIAN TU, is meant to help find a way to do that, by testing drugs on people with a family history and genes that make them likely to develop Alzheimer’s in their 50s, rather than after 65.

• One part will test the Roche Group’s biologic antibody drug gantenerumab, which removes amyloid beta plaques from the brain. It’s already in late-stage testing in patients who don’t have symptoms but have abnormally high levels of amyloid beta in spinal fluid.

• Another part will test Lilly’s solanezumab, which binds to smaller bits of amyloid beta and clears them from the brain before they clump into plaques.

• The third study drug could be Lilly’s BACE inhibitor, now in midstage testing in Alzheimer’s patients. The company expects by mid-2013 to complete work needed to determine whether the drug is right for the prevention study.

Meanwhile, two late-stage patient studies started this fall with a drug called LMTX developed by TauRx Pharmaceuticals Ltd. It targets tangles in the brain with an abnormal version of a protein called tau.

Thies, of the Alzheimer’s Association, thinks the disease likely is caused by a combination of those tau tangles and amyloid beta plaques.

The key issue for all these drugs will be what side effects they cause, because patients would take them for many years.

Patients and families are eager for a drug that slows or stops Alzheimer’s.

“When you’re faced with a diagnosis that tells you your brain is being eaten up,” said patient Ron Grant, “and you start seeing who you were no longer being who you are, and the only thing you can expect is being worse, in this day that’s totally unacceptable.”

The Oklahoma City prison chaplain was diagnosed with Alzheimer’s in 2007 at age 55 and had to stop work barely a year later. He’s helped found a support group for early onset Alzheimer’s patients, participated in a clinical trial and takes the drugs Namenda and Razadyne, which he thinks have limited his symptoms.

But PET scans of his brain show the disease is progressing. The former avid reader can no longer follow a book’s plot or remember where he left off.

The federal government doesn’t spend enough on Alzheimer’s, said Grant, who helps lobby Congress for more funding.

“The biggest thing standing between us and a treatment for this disease is money,” he said.

What's your take on the Packers Family Night change?

Retrieving results.
Watching practice is fine.(Your vote)
579 votes
I'd rather watch a scrimmage.(Your vote)
862 votes
I don't want to pay to watch practice.(Your vote)
1025 votes
It doesn't matter to me.(Your vote)
1279 votes

Catch up on the latest in our pregame show every game day.

Football fans

If you've ever answered "Who has the ball?" with "It's halftime," you might recognize The Airhead. Check out the characters in our cartoon gallery of oddball fans.

Special Reports


Football fans

If you've ever answered "Who has the ball?" with "It's halftime," you might recognize The Airhead. Check out the characters in our cartoon gallery of oddball fans.

Special Reports